Literature DB >> 17101938

Colorectal cancer screening in young patients with poor health and severe comorbidity.

Shahnaz Sultan1, Jason Conway, David Edelman, Tara Dudley, Dawn Provenzale.   

Abstract

BACKGROUND: Young patients with poor health and a high risk of mortality from comorbid diseases have less chance of deriving a survival benefit from colorectal cancer screening. The aim of this study was to examine the relationship between colorectal cancer screening, self-reported health status, and comorbidity in a cohort of young patients, defined as patients between the ages of 50 and 64 years.
METHODS: This was a single-center study conducted at a Veterans Affairs Medical Center from October 1, 1996, to March 30, 2004. Colorectal cancer screening information was obtained from 861 outpatients who completed the 36-Item Short-Form Health Survey (measure of health status) and the Kaplan-Feinstein Index (comorbidity score). Rates of screening were examined by age, physical component summary score, and severity of comorbid illnesses.
RESULTS: Of the veterans, 45.9% had undergone screening within 5 years of their index visit. Screening rates were high among patients with moderate (44.9%) and severe (45.8%) comorbidities. When stratified by age group and physical component summary quartile, there was a trend toward increasing screening rates with better health status in the 50- to 54- and 55- to 59-year age groups. In the 60- to 64-year age group, high screening rates for patients with poorer health were observed: physical component summary quartiles 1 and 2, 55.7% and 54.2%, respectively. Fifty-two patients died during the 5-year follow-up; 37 (71.2%) had undergone screening for colorectal cancer.
CONCLUSIONS: Young patients with potentially reduced life expectancy are being screened for colorectal cancer at relatively high rates. Comprehensive assessment of health status and comorbidity should guide cancer screening decisions, especially in individuals with reduced life expectancy who may obtain the least benefit from screening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101938     DOI: 10.1001/archinte.166.20.2209

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  Different effects of multiple health status indicators on breast and colorectal cancer screening in a nationally representative US sample.

Authors:  Anjali D Deshpande; Amy McQueen; Elliot J Coups
Journal:  Cancer Epidemiol       Date:  2011-11-11       Impact factor: 2.984

2.  Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.

Authors:  Kenneth J Smith; Mary Patricia Nowalk; Mahlon Raymund; Richard K Zimmerman
Journal:  Vaccine       Date:  2013-06-24       Impact factor: 3.641

3.  Depression screening as a quality indicator.

Authors:  Daniel J Luchins
Journal:  Ment Health Fam Med       Date:  2010-06

4.  The relationship between perceived burden of chronic conditions and colorectal cancer screening among Appalachian residents.

Authors:  Yelena N Tarasenko; Steven T Fleming; Nancy E Schoenberg
Journal:  J Rural Health       Date:  2013-06-28       Impact factor: 4.333

5.  Prevalence of colorectal cancer screening among a multimorbid rural Appalachian population.

Authors:  Steven T Fleming; Nancy E Schoenberg; Yelena N Tarasenko; Kevin A Pearce
Journal:  South Med J       Date:  2011-12       Impact factor: 0.954

6.  Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results.

Authors:  Hardeep Singh; Himabindu Kadiyala; Gayathri Bhagwath; Anila Shethia; Hashem El-Serag; Annette Walder; Maria E Velez; Laura A Petersen
Journal:  Am J Gastroenterol       Date:  2009-03-17       Impact factor: 10.864

7.  Provider recommendations for colorectal cancer screening in elderly veterans.

Authors:  Charles J Kahi; Michelle van Ryn; Beth Juliar; Jennifer Schaffter Stuart; Thomas F Imperiale
Journal:  J Gen Intern Med       Date:  2009-09-18       Impact factor: 5.128

8.  The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines.

Authors:  R Scott Braithwaite; David Fiellin; Amy C Justice
Journal:  Med Care       Date:  2009-06       Impact factor: 2.983

9.  Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems.

Authors:  S Yousuf Zafar; Amy P Abernethy; David H Abbott; Steven C Grambow; Jennifer E Marcello; James E Herndon; Krista L Rowe; Jane T Kolimaga; Leah L Zullig; Meenal B Patwardhan; Dawn T Provenzale
Journal:  BMC Cancer       Date:  2008-11-25       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.